| Future Health Pharma GmbH - Vaxelis 0.5 ml, Injektionssuspension | | 66940 | | 01 | | Vaxelis 0.5 ml | | Injektionssuspension | | J07CA09 | | Diphtheria-Haemophilus Influenzae B-Pertussis-Poliomyelitis-Tetanus-Hepatitis B | | 28.08.2019 | | |
| | Composition | | polysaccharida haemophili influenzae typus B conjugata cum proteino neisseriae meningitidis B 53 µg corresp. polysaccharida haemophili influenzae typus B 3 µg et neisseria meningitidis B outer membrane protein complex 50 µg, hepatitidis B viri antigenum ADNr 10 µg, toxoidum pertussis 20 µg, haemagglutininum filamentosum 20 µg, pertactinum 3 µg, fimbriae Typ 2 und 3 5 µg, toxoidum diphtheriae min. 20 U.I., toxoidum tetani min. 40 U.I., virus poliomyelitis typus 1 inactivatus (Mahoney) 40 U., virus poliomyelitis typus 2 inactivatus (MEF-1) 8 U., virus poliomyelitis typus 3 inactivatus (Saukett) 32 U., aluminium ut aluminii phosphas et aluminii hydroxyphosphas sulfas amorphus, natrii phosphates, acidum hydrochloridum q.s. ad pH, natrii hydroxidum q.s. ad pH, aqua ad iniectabile q.s. ad suspensionem pro 0.5 ml corresp. natrium 1.95 mg, residui: glutaralum, formaldehydum, neomycinum, streptomycinum, polymyxinum B, albuminum seri bovis, aluminii thiocyanas, faecis proteina. | | Packungsbestandteile | | Injection suspension | | | | | | | | Active Agent | Dose |
|---|
| | 20 µg | | | 10 µg | | Pertactin | 3 µg | | | 53 µg correspond 3 µg | | | 20 UI | | | 20 µg | | | 40 UI | | | 40 U | | | 8 U | | | 32 U |
| | BAG: Active Agent | Dose |
|---|
| | 5 mcg | | | 20 mcg | | | 3 mcg | | | 3 mcg | | | 20 mcg | | | 20 UI | | | 10 mcg | | | 40 UI | | | 40 U | | | 8 U | | | 32 U |
| | | | Inactive agents | Dose |
|---|
| | | | | | | Alumine | | | | 2 | | | | | | 50 µg | | | 5 µg |
| |
| |
|
